Contains Nonbinding Recommendations

Guidance on Abacavir Sulfate; Lamivudine; Zidovudine

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Abacavir Sulfate; Lamivudine; Zidovudine

Form/Route: Tablets/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 300 mg/150 mg/300 mg
   Subjects: Normal healthy males and females, general population.
   Additional Comments:

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 300 mg/150 mg/300 mg
   Subjects: Normal healthy males and females, general population.
   Additional comments:

Analytes to measure (in appropriate biological fluid): Abacavir, Lamivudine, and Zidovudine in plasma

Bioequivalence based on (90% CI): Abacavir, Lamivudine, and Zidovudine

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Finalized May 2008